drugset / Trial / NCT01797536

The Influence of Hepatic Insufficiency on the Pharmacokinetics of Elbasvir (MK-8742) (MK-8742-009)

NCT01797536

Phase 1 Completed 31 enrolled Merck Sharp & Dohme LLC Celerion · collab
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the pharmacokinetics (PK) profile of elbasvir (MK-8742) after a single dose to participants with mild, moderate, or severe hepatic insufficiency compared with healthy controls.

Timeline

Start
2013-03-06
Primary completion
2014-08-20
Completion
2014-08-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Elbasvir Small molecule 50 mg Oral

Indications